関連する実験動画
Updated: May 5, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 16, 2010
45.2K
ヒトにおける非対称性ダイメチルアルギニンによる全身性酸化窒素合成酵素抑制の心血管への影響
Jan T Kielstein1, Burcu Impraim, Solveig Simmel
1Department of Internal Medicine, Medical School Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. kielstein@yahoo.com
Circulation
|December 10, 2003
まとめ
健康な個人に非対称性ダイメチルアルギニン (ADMA) を注入すると,心臓の出力と腎臓の血流が一時的に低下します. これはまた,全身血管抵抗と血圧を増加させ,ADMAの心臓血管への影響を強調した.
科学分野:
- 心血管生理学 心血管の生理学
- 腎臓生理学 腎臓生理学
- エンドクリノロジー エンドクリノロジー
背景:
- 非対称性ジメチラーギニン (ADMA) の上昇は,心血管疾患と腎臓疾患の進行に関連しています.
- ADMAは,酸化窒素合成酵素 (NOS) の内生性阻害剤である.
研究 の 目的:
- 健康な被験者に対するADMA輸液の全身性心血管効果を評価する.
- 侵襲的方法を用いて,ADMAが心臓出力,腎機能,血管抵抗に与える影響を評価する.
主な方法:
- 健康な被験者は,ADMAの静脈注入を受けた.
- 右心経キャセテリゼーションおよびイヌリン/パラアミノヒプラートクリアランスを含む侵襲的な技術が採用されました.
- 測定には,心臓の出力,全身血管抵抗,腎臓の血流量,血圧などが含まれていた.
主要な成果:
- ADMAの注入により,プラズマのサイクルグアナシンモノフォスファート (cGMP) 濃度が著しく低下しました.
- 心臓の出力が低下し,全身血管抵抗と血圧が著しく上昇した.
- 腎臓のプラズマフローが減少し,腎血管抵抗が増加し,投与量に関係する効果を示した.
結論:
- システミックなADMA輸注は,心臓の出力量と腎臓のプラズマフローの短期的で控えめな減少を引き起こします.
- ADMAは,投与量に依存した方法で全身血管抵抗と血圧を増加させます.
- これらの発見は,ADMAの直接的な心血管および腎臓効果を強調しています.
さらに関連する動画
関連する概念動画
01:28Nitric Oxide Signaling Pathway
5.3K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.3K
01:23Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
01:16Antianginal Drugs: Nitrates and β-Blockers
1.9K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
823
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
823
01:26Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K